AS-1501

Phase IIa Main purpose: Evaluate the safety and tolerability of AS1501 for injection in subjects with early-stage acute-on-chronic liver failure (ACLF) and explore a reasonable dosing regimen. Determine the recommended dosing dose and frequency for Phase IIb. Secondary purpose: Preliminary evaluation of the efficacy, immunogenicity and pharmacokinetic (PK) characteristics of AS1501 for injection in the treatment of early-stage ACLF subjects. Preliminary exploration of the changes in serum TRAIL expression levels before and after administration of AS1501 for injection in early-stage ACLF subjects. Phase IIb Main purpose: Evaluate the efficacy of AS1501 for injection in the treatment of ACLF subjects. Secondary purpose: Evaluate the safety and PK characteristics of AS1501 for injection in the treatment of ACLF subjects. Explore the changes in serum TRAIL (TNF-related apoptosis-inducing ligand) expression levels before and after administration of AS1501 for injection in ACLF subjects.